Rep. Robert Bresnahan, Jr. Sells Off Shares of The Cigna Group (NYSE:CI)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of The Cigna Group NYSE: CI. In a filing disclosed on February 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in The Cigna Group stock on January 13th. The trade occurred in the Representative's "JOINT OWNERSHIP LPL ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Lowe's Companies NYSE: LOW on 2/7/2025.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Take-Two Interactive Software NASDAQ: TTWO on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 1/30/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/30/2025.
• Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 1/29/2025.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 1/29/2025.
• Sold $1,001 - $15,000 in shares of Manhattan Associates NASDAQ: MANH on 1/29/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 1/29/2025.

The Cigna Group Trading Up 0.9 %

Shares of CI stock traded up $2.52 during mid-day trading on Wednesday, hitting $297.27. 1,734,543 shares of the company's stock were exchanged, compared to its average volume of 1,810,551. The stock has a market cap of $82.69 billion, a price-to-earnings ratio of 24.29, a PEG ratio of 0.96 and a beta of 0.54. The company has a quick ratio of 0.72, a current ratio of 0.66 and a debt-to-equity ratio of 0.70. The Cigna Group has a fifty-two week low of $262.03 and a fifty-two week high of $370.83. The stock has a 50-day simple moving average of $285.58 and a two-hundred day simple moving average of $320.08.

The Cigna Group (NYSE:CI - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The health services provider reported $6.64 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.84 by ($1.20). The Cigna Group had a return on equity of 18.61% and a net margin of 1.39%. During the same period last year, the business earned $6.79 earnings per share. Equities analysts expect that The Cigna Group will post 29.77 EPS for the current fiscal year.

The Cigna Group Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Wednesday, March 5th will be paid a dividend of $1.51 per share. This represents a $6.04 dividend on an annualized basis and a dividend yield of 2.03%. The ex-dividend date is Wednesday, March 5th. This is a positive change from The Cigna Group's previous quarterly dividend of $1.40. The Cigna Group's dividend payout ratio is currently 45.75%.

Analyst Upgrades and Downgrades

CI has been the subject of several research reports. UBS Group lowered their price objective on shares of The Cigna Group from $410.00 to $390.00 and set a "buy" rating for the company in a research note on Monday, February 3rd. StockNews.com downgraded The Cigna Group from a "buy" rating to a "hold" rating in a report on Friday, January 31st. Royal Bank of Canada decreased their target price on The Cigna Group from $384.00 to $377.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Cantor Fitzgerald cut their price target on shares of The Cigna Group from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, January 31st. Finally, Piper Sandler reiterated an "overweight" rating and set a $348.00 price objective (down from $394.00) on shares of The Cigna Group in a research note on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, The Cigna Group has an average rating of "Moderate Buy" and a consensus price target of $373.69.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CI. GF Fund Management CO. LTD. purchased a new stake in The Cigna Group during the 4th quarter worth approximately $1,992,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of The Cigna Group during the fourth quarter worth approximately $3,585,000. Vega Investment Solutions bought a new stake in shares of The Cigna Group in the fourth quarter worth $304,000. Stonebridge Financial Planning Group LLC raised its holdings in The Cigna Group by 5.1% in the fourth quarter. Stonebridge Financial Planning Group LLC now owns 987 shares of the health services provider's stock valued at $273,000 after acquiring an additional 48 shares in the last quarter. Finally, Vise Technologies Inc. boosted its stake in The Cigna Group by 66.3% during the 4th quarter. Vise Technologies Inc. now owns 4,019 shares of the health services provider's stock valued at $1,110,000 after acquiring an additional 1,603 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.